Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.45 USD
Change Today -0.41 / -0.59%
Volume 699.6K
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
Stockholm
Mexico
Berlin
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (AZN) Key Developments

AstraZeneca to Invest USD 285 Million in New Pharmaceutical Factory in Sweden

AstraZeneca will invest approximately USD 285 million in a new manufacturing facility for its biologics in Sodertalje, Sweden. The facility, which is anticipated to become operational by 2019, is intended for filling and packaging of protein therapeutics, as well as supplying products for AstraZeneca and MedImmune's (the UK firm's biologics research and development unit) clinical studies from the end of 2018. Approximately 150-250 roles are expected to be created at the site by 2019. The expansion of the existing Sodertalje site to include a manufacturing facility for the company's biologics portfolio represents the first phase of a possible three-part programme to increase AstraZeneca's biologics production capabilities.

AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM

AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Irina Ivanishcheva, Legal Director.

AstraZeneca Russia Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 03:40 PM

AstraZeneca Russia Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 03:40 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Yuriy Mochalin, Corporate Affairs Director.

AstraZeneca to Collaborate with Abbott on Developing Companion Diagnostic Tests

AstraZeneca (UK) has entered into a collaboration deal with Abbott for developing companion diagnostic tests in order to identify patients with severe asthma, who are highly likely to benefit from a candidate drug, tralokinumab. According to the agreement, Abbott will be in charge of developing and commercialising diagnostic tests that measure serum levels of the proteins that have been identified as potential predictive biomarkers of up-regulated IL-13 in severe asthma - periostin and dipeptidyl peptidase-4 (DPP4). These diagnostic tests will be developed concurrently with the UK firm's Phase III study assessing tralokinumab for treating patients with severe, inadequately controlled asthma.

AstraZeneca PLC to Update on Progress with Immuno-Oncology Pipeline and Combination Treatments at ASCO 2015

AstraZeneca PLC announced that it will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts2 will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics. Highlights at the ASCO Annual Meeting will include data from across the Company’s broad pipeline of next-generation investigational medicines, which target cancer through key areas of tumor biology including immunotherapy, the genetic drivers of cancer and acquired resistance and DNA damage repair. Immunotherapies use the body's own immune system to help fight cancer. There are three major components to an effective cancer immune response: priming and activation of T-cells (white blood cells that play a central role in immune response) through cancer antigen presentation; optimizing T-cell mediated cancer cell killing by overcoming inhibitory mechanisms employed by the cancer; and overcoming immune suppressive mechanisms in the tumor microenvironment to further enhance an effective anti-tumor immune response. At the ASCO Annual Meeting AstraZeneca will provide an update on its comprehensive immuno-oncology development program, which includes 31 ongoing clinical trials targeted across this cycle of anti-tumor immunity. Data to be presented at ASCO are supported by a number of recent milestones including: Start of the combination arm of the Phase III ARCTIC study of MEDI4736 with tremelimumab in non-small cell lung cancer (NSCLC) patients who have received at least two prior systemic treatment regimens. Start of the Phase II CONDOR study of MEDI4736 and tremelimumab as monotherapies and in combination in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Fast-Track designation granted by the FDA for the investigation of MEDI4736 as a monotherapy treatment for patients with advanced NSCLC, who have received at least two prior systemic-treatment regimens, who do not have EGFR mutations or anaplastic lymphoma kinase (ALK) alterations, and have tumors that are determined to be PD-L1 positive. In addition to testing the potential of immunotherapies in solid tumors, AstraZeneca recently entered into a strategic collaboration [1] with Celgene, a global leader in haematological cancers, on a broad development program for MEDI4736, both as monotherapy and in combination with other molecules, across a range of blood cancers including multiple myeloma, non-Hodgkin’s lymphoma and myelodysplastic syndrome. Presentations to include: Safety and efficacy of MEDI4736 in combination with tremelimumabin patients with NSCLC. Updated data on additional patients and activity in both PD-L1 positive and negative patients to be presented. Safety and efficacy of the triple combination of MEDI4736 with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in patients with advanced melanoma. An open-label study of MEDI4736 in combination with MEDI0680 (anti-PD-1) in patients with advanced malignancies. Updates reinforcing the clinical activity of MEDI4736 as monotherapy in patients with NSCLC in patients with recurrent or metastatic SCCHN [Abstract #3011], and on the development of a PD-L1 companion diagnostic assay.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $69.45 USD -0.41

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €88.05 EUR +0.107
Biogen Inc $398.68 USD -2.47
Celgene Corp $116.09 USD -0.11
Eli Lilly & Co $74.30 USD +0.03
Valeant Pharmaceuticals International Inc C$291.64 CAD +6.41
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 68.5x
Price/Sales 3.4x
Price/Book 5.2x
Price/Cash Flow 68.5x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.